ALNY ALNYLAM PHARMACEUTICALS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1178670 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY65.2%
TTM net income YoY239.7%
TTM EPS YoY206.9%
Revenue 3-yr CAGR53.0%
Net income 3-yr CAGR—
Margins
Gross margin81.8%
Operating margin13.5%
Net margin10.5%
FCF margin11.8%
EBITDA margin15.0%
Returns
ROE90.8%
ROA8.4%
ROIC (approx.)—
Asset turnover0.81x
Leverage & solvency
Liabilities / assets84.1%
Debt / equity0.00x
Current ratio2.76x
Interest coverage1.58x
Cash quality & payout
Operating cash flow / net income1.28x
Accruals ratio-2.3%
Payout ratio—
Capex / revenue1.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $3.71B | $2.25B |
| Cost of revenue | $677.17M | $306.51M |
| Gross profit | $3.04B | $1.94B |
| R&D expense | $1.32B | $1.13B |
| SG&A expense | $1.21B | $975.53M |
| Operating income | $501.58M | -$176.88M |
| Interest expense | $252.63M | $141.86M |
| Pretax income | $323.15M | -$377.38M |
| Income tax | $9.40M | -$99.22M |
| Net income | $313.75M | -$278.16M |
| EBITDA | $557.24M | -$120.22M |
| EPS (basic) | 2.39 | -2.18 |
| EPS (diluted) | 2.33 | -2.18 |
| Weighted avg. shares (diluted) | 134.68M | 127.65M |
| Balance sheet | ||
| Cash & equivalents | $1.66B | $968.65M |
| Short-term investments | $1.25B | $1.72B |
| Receivables | $777.57M | $405.31M |
| Inventory | $82.72M | $78.51M |
| Current assets | $4.05B | $3.30B |
| PP&E, net | $513.15M | $502.78M |
| Total assets | $4.97B | $4.24B |
| Current liabilities | $1.47B | $1.19B |
| Total liabilities | $4.18B | $4.17B |
| Shareholders' equity | $789.18M | $67.09M |
| Shares outstanding | 132.38M | 129.29M |
| Cash flow statement | ||
| Operating cash flow | $524.08M | -$8.31M |
| Capital expenditure | $58.70M | $34.28M |
| Free cash flow | $465.38M | -$42.59M |
| Investing cash flow | $436.33M | -$116.84M |
| Financing cash flow | -$305.19M | $294.16M |
| Depreciation & amortization | $55.66M | $56.67M |
| Stock-based compensation | $348.24M | $272.08M |
Free plan shows the latest 2 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.